Literature DB >> 15893462

[Usefulness of procalcitonin for the diagnosis of acute pyelonephritis in children].

S Bigot1, P Leblond, C Foucher, V Hue, M D'Herbomez, M Foulard.   

Abstract

BACKGROUND: Acute pyelonephritis can induce parenchymal scarring. The aim of this study was to evaluate the usefulness of procalcitonin (PCT) to predict renal involvement in febrile children with urinary tract infection (UTI).
METHODS: In a prospective study serum PCT was measured and compared with others commonly used inflammatory markers in children admitted to the emergency unit with acute pyelonephritis. Renal parenchymal involvement was assessed by a (99 m)Tc-labeled dimercaptosuccinic acid (DMSA) renal scar performed in the first 3 days after the admission.
RESULTS: Among 42 enrolled patients, 19 (45%) had acute renal involvement (Group A) ; 23 (55%) (Group B) had normal DMSA scan (n = 16), or old scarring (n = 4) or various anomalies related to uropathy (n = 3). In group A, the mean PCT level was significantly higher than in the group B (5.4 ng/ml, vs 0.4 ng /ml, p < 10(-5)). In these 2 groups, mean C reactive protein (CRP) levels were 99.1 mg/l and 44.6 mg/l respectively (p < 0.001). For a level of serum PCT > or = 0.5 ng/ml, the sensitivity and specificity to predict the renal involvement were 100% and 87% respectively; for a level> or= 20 mg/l CRP had a sensitivity of 94% but a specificity of 30%.
CONCLUSION: Serum PCT levels were significantly increased in febrile children with UTI when acute renal parenchymal involvement was present. PCT seems a better marker than CRP for the prediction of patients at risk of renal lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893462     DOI: 10.1016/j.arcped.2005.03.058

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  8 in total

1.  Diagnostic significance of clinical and laboratory findings to localize site of urinary infection.

Authors:  Eduardo H Garin; Fernando Olavarria; Carlos Araya; Monica Broussain; Claudia Barrera; Linda Young
Journal:  Pediatr Nephrol       Date:  2007-03-21       Impact factor: 3.714

Review 2.  Diagnostic value of serum procalcitonin for acute pyelonephritis in infants and children with urinary tract infections: an updated meta-analysis.

Authors:  Huhai Zhang; Jurong Yang; Lirong Lin; Bengang Huo; Huanzi Dai; Yani He
Journal:  World J Urol       Date:  2015-07-04       Impact factor: 4.226

Review 3.  Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children.

Authors:  Nader Shaikh; Jessica L Borrell; Josh Evron; Mariska M G Leeflang
Journal:  Cochrane Database Syst Rev       Date:  2015-01-20

4.  Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children.

Authors:  Kai J Shaikh; Victor A Osio; Mariska Mg Leeflang; Nader Shaikh
Journal:  Cochrane Database Syst Rev       Date:  2020-09-10

5.  Procalcitonin as a predictor of renal scarring in infants and young children.

Authors:  Silvia Bressan; Barbara Andreola; Pietro Zucchetta; Giovanni Montini; Marta Burei; Giorgio Perilongo; Liviana Da Dalt
Journal:  Pediatr Nephrol       Date:  2009-02-10       Impact factor: 3.714

6.  Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results.

Authors:  Aggeliki Kotoula; Stefanos Gardikis; Aggelos Tsalkidis; Elpis Mantadakis; Athanassios Zissimopoulos; Katerina Kambouri; Savvas Deftereos; Gregorios Tripsianis; Konstantinos Manolas; Athanassios Chatzimichael; George Vaos
Journal:  Int Urol Nephrol       Date:  2008-10-03       Impact factor: 2.370

7.  Procalcitonin: a key marker in children with urinary tract infection.

Authors:  Sandrine Leroy; Alain Gervaix
Journal:  Adv Urol       Date:  2011-01-17

8.  Prediction of high-grade vesicoureteral reflux after pediatric urinary tract infection: external validation study of procalcitonin-based decision rule.

Authors:  Sandrine Leroy; François Bouissou; Anna Fernandez-Lopez; Metin K Gurgoze; Kyriaki Karavanaki; Tim Ulinski; Silvia Bressan; Geogios Vaos; Pierre Leblond; Yvon Coulais; Carlos Luaces Cubells; A Denizmen Aygun; Constantinos J Stefanidis; Albert Bensman; Liviana Da Dalt; Liviana DaDalt; Stefanos Gardikis; Sandra Bigot; Dominique Gendrel; Gérard Bréart; Martin Chalumeau
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.